North America ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption, Test Type, Application, and End User

The North America ELISA diagnostics tests market was valued at US$ 554.69 million in 2022 and is expected to reach US$1.00 billion by 2030; it is estimated to grow at a CAGR of 7.8% from 2022 to 2030.

Rising Infectious Diseases Among Animals Fuel North America ELISA Diagnostics Tests Market

According to the Centers for Disease Control and Prevention (CDC) report, enteric diseases linked to animals or environments account for 450,000 case of illnesses, 5,000 hospitalizations, and 76 deaths among humans in the US alone. These illnesses are observed in humans in contact with animal feces or body fluids, and the pathogens transmitted through animal contact can prove dangerous for humans. Additionally, the World Organization for Animal Health published a report revealing that 60% of human infections comprise animal-related diseases. It also mentioned that 75% of emerging animal diseases can be transmitted to humans, and there are five emerging diseases among animals annually. Every year, about 55,000 healthcare claims are associated with rabies infection worldwide, comprising mainly children due to infected dog bites as per the WHO report. Further, the Health for Animals report reveals that six animal-related diseases (Hantavirus, Lymphocytic, Choriomeningitis virus (LCMV), plague, salmonella, rat bite fever, and tularemia) caused economic losses worth US$ 80 billion within 12 years. Among six, just one animal-related disease, "Foot and Mouth," costs farmers up to US$ 21 billion globally every year. The persistent lymphocytosis (PL) present among cows can infect their calves during pregnancy. Cows can suffer from serious milk production declines and may infect other surrounding animals. In this scenario, Enzyme-Linked Immunosorbent Assay (ELISA) test is best suited to test infected cow's positive for PL disease as it reveals proper lymphocyte count clinical results on testing. Further, the test is reported by veterinarian to be 95% sensitive for animals infected with 55 days of infection. Therefore, ELISA test is commonly recommended by veterinarian for animals aged 8 months and above. Thus, rising incidence of animal-associated diseases propels the demand for ELISA tests.

North America ELISA Diagnostics Tests Market Overview

The ClinMed International Library 2017 report reveals that "Giardia Intestinalis" is the most common intestinal parasitic infection in the US. Moreover, in the country, 22.5% of the population over 12 years of age gets infected with "Toxoplasma Gondii". Further, in the last two decades, there has been a rise in the incidence of zoonotic diseases in the US, becoming a significant cause of rising infectious disease cases among the US population. Additionally, the CDC 2023 report reveals that the incidence of avian influenza (AI) was on the rise in the US in January 2022. It stated that 59,031,321 birds were affected due to AI in the US as per the CDC report. Therefore, to control AI infections in the US, commercial ELISA test kits were made available to confirm any positives. Thus, rising incidences of infectious diseases among humans due to high zoonotic disease cases boost the adoption of ELISA diagnostic tests in the US.

North America ELISA Diagnostics Tests Market Segmentation

The North America ELISA diagnostics tests market is segmented based on adoption, test type, application, end user, and country. Based on adoption, the North America ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held a larger market share in 2022.

In terms of test type, the North America ELISA diagnostics tests market is segmented into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held the largest market share in 2022.

Based on application, the North America ELISA diagnostics tests market is segmented into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held the largest market share in 2022.

By end user, the North America ELISA diagnostics tests market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held the largest market share in 2022.

Based on country, the North America ELISA diagnostics tests market is segmented into the US, Canada, and Mexico. The US dominated the North America ELISA diagnostics tests market share in 2022.

Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., Pictor Ltd., DiaSorin SpA, Elabscience Biotechnology Inc., and Bio-Techne Corp are some of the leading companies operating in the North America ELISA diagnostics tests market.